Trevena Inc.

News & Events

Press Releases

In The Media

1. Trevena Reports Third Quarter 2024 Results and Provides Business Update

   GlobeNewswire NOV 7, 2024 7:01 AM EST
   CHESTERBROOK, Pa., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceu...
   READ ARTICLE

2. Trevena Announces Receipt of Nasdaq Delisting Notification

   GlobeNewswire OCT 4, 2024 4:05 PM EDT
   CHESTERBROOK, Pa., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharm...
   READ ARTICLE

3. Trevena Announces Reverse Stock Split

   GlobeNewswire AUG 8, 2024 4:05 PM EDT
   CHESTERBROOK, Pa., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharm...
   READ ARTICLE

4. Trevena Reports Second Quarter 2024 Results and Provides Business Update

   GlobeNewswire AUG 8, 2024 7:00 AM EDT
   TRV045, novel S1P receptor modulator in development for the treatment of acute and chronic neurop...
   READ ARTICLE

5. Sagimet Biosciences Announces Appointment of Anne Phillips and Jennifer Jarrett to its Board of Directors

   GlobeNewswire AUG 1, 2024 8:00 AM EDT
   SAN MATEO, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: S...
   READ ARTICLE

6. Trevena Announces $2M Non-Dilutive Financing Tranche and Reduction in Outstanding Liabilities in Connection with Existing ex-US Royalty Financing

   GlobeNewswire JUL 8, 2024 9:15 AM EDT
   Trevena expects to receive a non-dilutive $2 million tranche and may be eligible for up to an add...
   READ ARTICLE

7. Trevena Announces Preclinical TRV045 Data Providing Insight Into Novel Mechanism of Analgesic Effect in Chronic Neuropathic Pain Model and Demonstrating Statistically Significant Anti-Seizure Activity in Epilepsy Models

   GlobeNewswire JUN 20, 2024 7:00 AM EDT
   TRV045 shows potential for sustained, long-term analgesic effect in preclinical model of neuropat...
   READ ARTICLE

8. Trevena Reports First Quarter 2024 Results and Provides Business Update

   GlobeNewswire MAY 15, 2024 7:00 AM EDT
   TRV045, novel S1P receptor modulator for chronic pain and epilepsy, continues to demonstrate a fa...
   READ ARTICLE

9. SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Trevena, Inc. of Class Action Lawsuit and Upcoming Deadline - TRVN

   Canada Newswire NOV 7, 2018 6:23 PM EST
   SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment...
   READ ARTICLE

10. Trevena, Inc. (NASDAQ:TRVN) Completes Phase 3 Apollo Trials for Oliceridine, Says Athena Study on Track

    ABN Newswire JAN 11, 2017 5:28 PM EST
    New York, United States (ABN Newswire) - (NetworkNewsWire) Trevena, Inc. (NASDAQ:TRVN), a cli...
    READ ARTICLE